ArticleJournal of thoracic disease2025
The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemoptysis is associated with a variety of respiratory system diseases. Bronchial artery embolization (BAE) is effective for this condition, and preoperative computed tomography angiography (CTA) is helpful for the implementation of BAE. Some non-life-threatening cases have intermittent and recurrent episodes after conservative treatment, and no obvious abnormalities were found during tests and examinations, and they were defined as upper lobe-origin hemoptysis (ULOH), with concerns of embolism. This study aimed to describe the clinical characteristics of a distinct subtype of hemoptysis patients, termed ULOH, as well as the efficacy and outcomes of these patients after BAE. Methods: From April 2019 to March 2024, a total of 31 consecutive ULOH patients who suffered varying episodes of relapse after conservative treatment and then received BAE were included. After the procedure, each case underwent respiratory rehabilitation, followed by dual-energy computed tomography (DECT)to quantitatively assess pulmonary function. Patients' demographics, clinical characteristics, imaging findings, details of BAE, and outcomes were reviewed and summarized. Results: The median age was 49.0 years old. Twenty-eight patients (90.3%) were male, and 22 (71.0%) cases were heavy smokers. CTA indicated that hemorrhage of alveoli was confined to the upper lobes, and the diameter of all bronchial arteries was no more than 2.0 mm. During bronchial artery angiography, each case showed symmetrical characteristic of systemic-pulmonary shunt (SPS) at bilateral apexes. One month after embolization, chest computed tomography (CT) scan demonstrated complete resolution of the lesion. All patients received 6 months of respiratory rehabilitation after procedures, and the followed integrated analysis of DECT showed structure and function were normal. During a median follow-up period of 24 months, no patient experienced hemoptysis recurrence. Conclusions: Patients with ULOH presented as normal diameter of bronchial arteries and symmetrical characteristic of SPS at bilateral apexes during angiography. After BAE procedure, these patients could harvest complete recovery in both structure and function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.